Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

  • Caballero-Camino, F. J.
  • Rivilla, I.|||0000-0003-1984-7183
  • Herraez, Elisa
  • Briz, O.
  • Santos-Laso, A.|||0000-0001-9810-4913
  • Izquierdo-Sanchez, Laura
  • Lee-Law, P. Y.
  • Rodrigues, P. M.|||0000-0001-6193-7436
  • Munoz-Garrido, P.
  • Jin, S.
  • Peixoto, E.
  • Richard, S.
  • Gradilone, S. A.
  • Perugorria, M. J.
  • Esteller, M.|||0000-0003-4490-6093
  • Bujanda, Luis|||0000-0002-4353-9968
  • Marin, J. J. G.
  • Banales, Jesus|||0000-0002-5224-2373
  • Cossío, Fernando P.|||0000-0002-4526-2122
Background and Aims: Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results: Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions: These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The epidermal growth factor receptor ligand amphiregulin protects from cholestatic liver injury and regulates bile acids synthesis

  • Santamaría, Eva
  • Rodriguez-Ortigosa, Carlos
  • Uriarte, Iker
  • Latasa, Maria Ujue
  • Urtasun Alonso, Raquel
  • Álvarez-Sola, Gloria
  • Bárcena-Varela, Marina
  • Colyn, Leticia
  • Arcelus, Sara
  • Jiménez, Maddalen
  • Deutschmann, Kathleen
  • Peleteiro Vigil, Ana
  • Gómez Cambronero, Julián
  • Milkiewicz, Malgorzata
  • Milkiewicz, Piotr
  • Sangro, Bruno
  • Keitel, Verena
  • Monte, María J.
  • Marin, Jose J. G.
  • Fernández-Barrena, Maite G.
  • Ávila, Matías A.
  • Berasain, Carmen
Intrahepatic accumulation of bile acids (BAs) causes hepatocellular injury. Upon liver damage, a potent protective response is mounted to restore the organ’s function. Epidermal growth factor receptor (EGFR) signaling is essential for regeneration after most types of liver damage, including cholestatic injury. However, EGFR can be activated by a family of growth factors induced during liver injury and regeneration. We evaluated the role of the EGFR ligand, amphiregulin (AREG), during cholestatic liver injury and regulation of AREG expression by BAs. First, we demonstrated increased AREG levels in livers from patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). In two murine models of cholestatic liver injury, bile duct ligation (BDL) and alpha‐naphthyl‐isothiocyanate (ANIT) gavage, hepatic AREG expression was markedly up‐regulated. Importantly, Areg–/– mice showed aggravated liver injury after BDL and ANIT administration compared to Areg+/+ mice. Recombinant AREG protected from ANIT and BDL‐induced liver injury and reduced BA‐triggered apoptosis in liver cells. Oral BA administration induced ileal and hepatic Areg expression, and, interestingly, cholestyramine feeding reduced postprandial Areg up‐regulation in both tissues. Most interestingly, Areg–/– mice displayed high hepatic cholesterol 7 α‐hydroxylase (CYP7A1) expression, reduced serum cholesterol, and high BA levels. Postprandial repression of Cyp7a1 was impaired in Areg–/– mice, and recombinant AREG down‐regulated Cyp7a1 mRNA in hepatocytes. On the other hand, BAs promoted AREG gene expression and protein shedding in hepatocytes. This effect was mediated through the farnesoid X receptor (FXR), as demonstrated in Fxr–/– mice, and involved EGFR transactivation. Finally, we show that hepatic EGFR expression is indirectly induced by BA‐FXR through activation of suppressor of cytokine signaling‐3 (SOC3). Conclusion: AREG‐EGFR signaling protects from cholestatic injury and participates in the physiological regulation of BA synthesis., Grants SAF 2016-75972R from Ministerio de Economía y Competitividad, Spain. Grants FIS PI16/01126 and PI16/00598 from Instituto de Salud Carlos III (ISCIII).